Vaccine Contract Manufacturing Market Size, Share, Trend, Revenue Report 2026 to 2035

What is Vaccine Contract Manufacturing Market Size?

Vaccine Contract Manufacturing Market Size is valued at USD 2.37 Bn in 2025 and is predicted to reach USD 4.65 Bn by the year 2035 at a 7.30% CAGR during the forecast period for 2026 to 2035. 

Vaccine Contract Manufacturing Market Size, Share & Trends Analysis Report By Vaccine Type (Attenuated, Inactivated, Subunit-based, Toxoid-based, DNA-based), By Type of Expression System, By Workflow, By Application, By Region, And By Segment Forecasts, 2026 to 2035.

Key Industry Insights & Findings from the Report:

• The vaccine contract manufacturing market is experiencing significant growth driven by increasing demand for vaccines globally,
• Asia-Pacific is anticipated to exhibit the most rapid (CAGR) throughout the forecast period.
• In terms of Vaccine Type, the attenuated vaccines segment has captured the largest portion of revenue.
• The inactivated inoculations segment is forecasted to experience significant expansion at an impressive CAGR by Vaccine Type.
• Within the Workflow category, the downstream segment has contributed the highest revenue share.
• Meanwhile, within the Workflow category, the upstream segment is expected to demonstrate the swiftest Compound Annual Growth Rate (CAGR) over the projected duration.

Vaccine contract manufacturing plays a vital role in the pharmaceutical industry, contributing to the efficient and scalable production of vaccines to address various health challenges worldwide. With the expanding efforts in global vaccine distribution, the ability to manage various facets of vaccine manufacturing and logistics positions Contract Manufacturing Organizations (CMOs) to play an important role in ensuring fair access to vaccines worldwide. Consequently, diversifying services becomes a strategic manoeuvre that not only enhances the market presence of CMOs but also contributes to addressing global health challenges. Additionally, advancements in vaccine technology, driven by innovations such as genetic engineering, vaccine delivery technology, and proteomics, continue to shape the industry's dynamic landscape. 

Moreover, the increasing implementation of strategic initiatives by key industry players, including activities such as business expansion, partnerships, and acquisitions, also reinforces the projected market growth. The rising global demand for vaccine contract manufacturing is set to propel market expansion.

Competitive Landscape

Some Major Key Players In The Vaccine Contract Manufacturing Market:

• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Ajinomoto Althea, Inc.
• Merck KgaA
• Cytovance Biologics
• Catalent, Inc.
• IDT Biologika GmbH
• Albany Molecular Research, Inc.
• PRA Health Sciences
• ICON plc.
• Pharmaceutical Product Development, LLC
• Cobra Bio
• Paragon Bioservices, Inc.
• Charles River Laboratories
• Meridian Life Science (MLS)
• Eurogentec
• GreenPak Biotech
• Hong Kong Institute of Biotechnology
• WuXi Biologics
• Bharat Biotech
• Biological E
• Others

Market Segmentation

The global market of vaccine contract manufacturing is segmented on the basis of Vaccine Type, Type of Expression System, Workflow, and Application. The vaccine Type segment is categorised into Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based. By Type of Expression System, the market is segmented into Avian Expression Systems, Bacterial Expression Systems, Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs), Insect Expression Systems, Mammalian Expression Systems, Plant Expression Systems, and Yeast Expression Systems. The Workflow segment consists of Downstream and Upstream. As per the Application segment, the market is divided into Human Use and Veterinary.

The Segment Of Inactivated Vaccines Is Projected To Dominate The Market For Vaccine Contract Manufacturing During The Forecast Period.

Inactivated vaccinations consist of whole bacteria or viruses rendered non-viable or altered to prevent reproduction. Due to the absence of live bacteria or viruses, these vaccines are incapable of transmitting the diseases they are designed to protect against, even in individuals with severely weakened immune systems. This characteristic represents a significant benefit of this vaccine category.

Based On The Type Of Expression Systems, The Mammalian Segment Is A Major Contributor To The Vaccine Contract Manufacturing Market. 

The mammalian category is expected to hold a major share of the global Vaccine Contract Manufacturing market in 2024. The increasing prominence of mammalian cell culture technology has become a notable trend in the vaccine contract manufacturing market. Mammalian cell culture is gaining significance as a preferred method for vaccine production due to its ability to replicate complex biological systems and produce a wide range of proteins. This technology offers advantages such as enhanced yield, scalability, and the ability to produce more complex and effective vaccines. As a result, the rising utilization of mammalian cell culture in vaccine contract manufacturing is shaping the landscape of the market, contributing to its growth and innovation. This trend underscores the industry's ongoing efforts to improve vaccine manufacturing processes and meet the growing demand for safe and effective vaccines.

The Human-Use Segment Witnessed Growth At A Rapid Rate.

In recent years, the human-use category has dominated the market with the highest share. The extensive immunization coverage against various diseases in humans has resulted in this sector gaining the leading position in the market.

In The Region, The North America Vaccine Contract Manufacturing Market Holds A Significant Revenue Share.

The North America Vaccine Contract Manufacturing market is expected to register the highest market share. Advantages include a well-established biotechnology and pharmaceutical sectors, a sizable population, and a strong emphasis on healthcare that drives up vaccine demand. The area is a desirable location for contract manufacturing organizations (CMOs) due to its advanced manufacturing infrastructure, highly qualified labour, and well-established regulatory frameworks. Leading vaccine developers and government programs to support vaccine production reinforce North America's leading position in the market and establish it as a main driver of the sector's expansion. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Vaccine Contract Manufacturing market.

The area gains from having highly qualified labourers and sophisticated manufacturing resources. Furthermore, it is a desirable location for vaccine contract manufacturing due to its favourable regulatory conditions and lower labour costs. Hence, Asia-Pacific continues to play a significant role in expanding the global vaccine contract manufacturing market. 

Recent Developments:

• In Oct 2023, Vaxcyte, Inc. and Lonza have recently established a fresh commercial production arrangement. This partnership further facilitates the eventual worldwide commercialization of Vaxcyte's PCV candidates, VAX-24 and VAX-31, in both adults and children. This arrangement enhances Vaxcyte's strategy to leverage Lonza's existing infrastructure for the purpose of accelerating clinical development and facilitating the expected initial introduction of VAX-24 for the adult demographic in the United States.

• In March 2021, Catalent has enhanced its collaboration with Johnson & Johnson to substantially augment the capability for sterile production and packaging of the COVID-19 vaccine in Italy. Catalent and Janssen had already reached an agreement to allocate an already existing vial-filling line at the Anagni factory.

Vaccine Contract Manufacturing Market Report Scope